Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS News
  • Diltiazem use tied to...

Diltiazem use tied to serious bleeding risk in atrial fibrillation patients on apixaban or rivaroxaban: JAMA

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-04-26T09:45:57+05:30  |  Updated On 26 April 2024 9:46 AM IST
Odisha Government Allocates Rs 23,635 Crore for Health

Odisha Government Allocates Rs 23,635 Crore for Health

  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

USA: A recent study published in the Journal of the American Medical Association (JAMA) has revealed an increased risk of serious bleeding compared with metoprolol with diltiazem treatment among older adults with atrial fibrillation (AF) receiving rivaroxaban or apixaban.

"In the cohort study of 204 155 patients aged 65 years or older, those treated with diltiazem had a significantly higher risk of serious bleeding compared with those treated with metoprolol," the researchers reported.

Atrial fibrillation is a common cardiac arrhythmia characterized by irregular heartbeats, which can increase the risk of stroke due to the formation of blood clots in the atria. To mitigate this risk, anticoagulant therapy is often prescribed. Two widely used anticoagulants for AF are apixaban and rivaroxaban. However, when AF patients on these anticoagulants experience serious bleeding, particularly while also taking diltiazem, managing the situation becomes complex.

Diltiazem is a commonly prescribed ventricular rate–control medication for AF patients, inhibits apixaban and rivaroxaban elimination, possibly causing over-anticoagulation.

Against the above background, Wayne A. Ray, Vanderbilt University School of Medicine, Nashville, Tennessee, and colleagues aimed to compare serious bleeding risk for new users of rivaroxaban or apixaban with atrial fibrillation treated with diltiazem or metoprolol.

For this purpose, the researchers conducted a retrospective cohort study including Medicare beneficiaries aged 65 years or older with AF who initiated rivaroxaban or apixaban use and began treatment with metoprolol or diltiazem between 2012 and 2020. Patients were followed for 365 days.

A total of 204 155 US Medicare beneficiaries were included, of whom 53 275 received diltiazem and 150 880 received metoprolol. Study patients (mean age, 76.9 years; 52.7% female) had 90 927 person-years (PY) of follow-up (median, 120 days).

The study's primary outcome was a composite of bleeding-related hospitalization and death with recent evidence of bleeding. Secondary outcomes included major ischemic or hemorrhagic events (ischemic stroke, intracranial or fatal extracranial bleeding, systemic embolism, or death with recent evidence of bleeding), systemic embolism or ischemic stroke, and death without recent evidence of bleeding.

Hazard ratios (HRs) and rate differences (RDs) were adjusted for covariate differences with overlap.

Following were the study’s key findings:

  • Patients receiving diltiazem treatment had increased risk for the primary outcome (RD, 10.6 per 1000 PY; HR, 1.21) and its components of bleeding-related hospitalization (RD, 8.2 per 1000 PY; HR, 1.22) and death with recent evidence of bleeding (RD, 2.4 per 1000 PY; HR, 1.19) compared with patients receiving metoprolol.
  • The risk for the primary outcome with initial diltiazem doses exceeding 120 mg/d (RD, 15.1 per 1000 PY; HR, 1.29) was greater than that for lower doses (RD, 6.7 per 1000 PY; HR, 1.13).
  • For doses exceeding 120 mg/d, the risk of major ischemic or hemorrhagic events was increased (HR, 1.14).
  • Neither dose group had significant changes in the risk for ischemic stroke or systemic embolism, or death without recent evidence of bleeding.
  • When patients receiving high- and low-dose diltiazem treatment were directly compared, the HR for the primary outcome was 1.14.

"Diltiazem was associated with a greater risk of serious bleeding than metoprolol, particularly for diltiazem doses exceeding 120 mg/d in Medicare patients with atrial fibrillation receiving apixaban or rivaroxaban," the researchers concluded.

Reference:

Ray WA, Chung CP, Stein CM, et al. Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban. JAMA. Published online April 15, 2024. doi:10.1001/jama.2024.3867

Journal of the American Medical Association (JAMA)atrial fibrillationdiltiazemrivaroxabanapixabanserious bleedingmetoprolol
Source : Journal of the American Medical Association (JAMA)
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    View All

    Journal Club Today

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Health News Today

    Health Bulletin 09/ May/ 2025

    Health Bulletin 09/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok